This article is for informational and educational purposes only and does not constitute medical advice. Bronchogen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Bronchogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Leu (AEDL) and a molecular weight of approximately 446 Da. It belongs to the peptide bioregulator class developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, originally derived from research on bovine bronchial tissue extracts. The compound is proposed to function as a respiratory-specific peptide bioregulator with the capacity to modulate gene expression in bronchial epithelial cells. Preclinical studies from the originating research group have reported effects on bronchial epithelial cell viability and gene expression markers in vitro, with proposed applications in respiratory epithelium biology research. The proposed mechanism is framed within the Khavinson bioregulator hypothesis that short peptides derived from target organ extracts regulate gene transcription through complementary interactions with promoter DNA sequences. As with other members of this compound class, the published evidence base is largely confined to the originating research group, independent replication by external laboratories has not been widely reported in peer-reviewed literature, and no regulatory authority has approved Bronchogen for any clinical indication.
1. Background
1.1 The Peptide Bioregulator Concept
Bronchogen belongs to the Khavinson peptide bioregulator class — a series of short synthetic peptides proposed to regulate gene expression in a tissue-specific manner by interacting with promoter regions of DNA. The theoretical framework, developed beginning in the Soviet Union in the 1970s and continuing through the post-Soviet Russian scientific program, holds that short peptides derived from organ extracts carry sequence-specific information that modulates transcription in the corresponding target tissue. For a broader review of the bioregulator class and its methodological context, see the companion articles on Epitalon (AEDG) and Pinealon (EDR).
Bronchogen was developed as a derivative of a peptide fraction isolated from bovine bronchial tissue. Its four-amino-acid sequence Ala-Glu-Asp-Leu shares the first three residues (Ala-Glu-Asp) with several other Khavinson bioregulators, including Epitalon (Ala-Glu-Asp-Gly) and Cardiogen (Ala-Glu-Asp-Arg). Within the Khavinson framework, the differing C-terminal residue — leucine in Bronchogen — is proposed to confer bronchial tissue specificity, though the molecular basis for such tissue-selective targeting has not been established by independent structural biology experiments.
1.2 Respiratory Epithelium Biology and the Rationale for Bronchial Bioregulation
The bronchial epithelium is a pseudostratified layer lining the conducting airways from the trachea to the terminal bronchioles. It performs multiple functions essential to respiratory homeostasis: mucociliary clearance of inhaled particles and pathogens through coordinated ciliary beating; secretion of mucus, antimicrobial peptides, and cytokines; and serving as the primary physical barrier between inhaled air and the underlying submucosa. The epithelium is composed of several cell types, including ciliated cells, mucus-secreting goblet cells, club cells (formerly Clara cells), and basal cells that serve as tissue-resident progenitors capable of renewing the epithelial layer following injury.
In contrast to cardiomyocytes, bronchial epithelial cells retain meaningful regenerative capacity throughout adult life, primarily through basal cell proliferation and differentiation. Aging, chronic inflammation, tobacco exposure, and environmental pollutants progressively impair this renewal capacity, contributing to diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis, and increased susceptibility to respiratory infection. The Khavinson group’s rationale for developing a bronchial-targeted bioregulator was grounded in the hypothesis that a peptide derived from bronchial tissue might support or restore gene expression patterns associated with epithelial function and protection.
2. Molecular Structure
| Property | Value |
|---|---|
| Full name | Bronchogen |
| Sequence (single-letter) | AEDL |
| Sequence (full names) | Ala-Glu-Asp-Leu |
| Molecular weight | ~446 Da |
| Molecular formula | C ₁₈H ₃₀N ₄O ₉ |
| Peptide length | 4 amino acids (tetrapeptide) |
| Net charge (physiological pH) | −2 (two acidic residues at positions 2–3; no basic side chains) |
| Origin | Synthetic; sequence derived from bovine bronchial tissue extract research |
| Proposed primary target | Bronchial epithelial cell gene promoter regions (proposed); respiratory tissue-specific transcription |
| Related compounds | Epitalon (AEDG), Cardiogen (AEDR) — share Ala-Glu-Asp N-terminal tripeptide |
The net charge of −2 at physiological pH mirrors that of Epitalon (AEDG), as both sequences carry glutamic acid and aspartic acid at positions 2 and 3 without a compensating basic residue at position 4. In Bronchogen, leucine at the C-terminal position contributes a bulky aliphatic side chain that is hydrophobic and uncharged, distinguishing it from Epitalon’s glycine (minimally sized, no side chain) and Cardiogen’s arginine (basic, positively charged). Within the Khavinson theoretical framework, this hydrophobic C-terminal residue is proposed to influence the tissue-targeting selectivity of the AEDL peptide, though no experimental evidence for leucine-dependent bronchial selectivity has been published by independent investigators.
3. Proposed Mechanisms of Action
4. Key Research Findings
4.1 In Vitro Bronchial Epithelial Studies
The primary in vitro evidence base for Bronchogen centers on studies using bronchial epithelial cell culture models. The Khavinson group has published work reporting that AEDL treatment in these systems is associated with changes in markers of cell viability, gene expression profiles relevant to bronchial epithelial function, and protein synthesis activity [1]. These in vitro observations form the basis for the proposed mechanisms described above and provide the mechanistic foundation for extending Bronchogen research to more complex experimental preparations.
A consistent feature of this in vitro literature is that the studies originate predominantly from a single research group. Replication of key findings by independent respiratory biology laboratories using contemporary methods — including RNA sequencing, single-cell transcriptomics, organoid models of bronchial epithelium, and air-liquid interface culture systems that more closely replicate in vivo airway biology — has not been reported in peer-reviewed literature. The experimental systems used in the Khavinson publications predate several of these methodological advances.
4.2 Animal Respiratory Models
Animal model studies from the Khavinson group have examined Bronchogen in experimental preparations designed to assess respiratory epithelial function and lung tissue integrity. Reported outcomes have included histological assessments of bronchial epithelial morphology, measurements of inflammatory cell infiltration, and functional indices of respiratory tissue in aged or challenged animal models [2]. These studies provide a more integrative view of Bronchogen’s proposed effects than cell culture alone, but are subject to the same single-group limitation that characterizes the broader Khavinson bioregulator literature.
Rodent respiratory models differ from the complex, multifactorial pathophysiology of human chronic airway diseases, which typically involve decades of cumulative environmental exposure, comorbid systemic conditions, and heterogeneous inflammatory and remodeling processes. Translation of animal model findings to human respiratory disease contexts therefore involves substantial uncertainty.
Schematic representation of evidence depth at each research stage. Bar lengths are qualitative, not derived from a numerical index. Independent replication in each category is absent or minimal as of the review date.
4.3 Published Human Data
Published human data relevant to Bronchogen are very limited. No peer-reviewed, randomized, placebo-controlled trial of Bronchogen in human subjects has been identified as of the review date. The Khavinson group has included respiratory bioregulators in broader observational reports examining bioregulator peptide use in clinical populations, but controlled trials with Bronchogen as the primary intervention and respiratory endpoints as pre-registered primary outcomes have not been identified [3].
The absence of controlled human trial data means no assessment of safety, tolerability, pharmacokinetics, or respiratory efficacy in human subjects can be drawn from the published evidence. This is particularly relevant given the availability of established and extensively studied interventions for common chronic airway conditions, against which any novel respiratory compound would need to be evaluated.
5. Evidence Status
| Proposed Effect | Current Status | Evidence Level |
|---|---|---|
| Bronchial epithelium gene expression modulation | Reported in vitro by Khavinson group; no independent replication published | Limited |
| Bronchial epithelial cell viability support | In vitro observations from originating group; mechanism not independently characterized | Limited |
| Mucosal barrier function influence | Preclinical data from Khavinson group; functional significance in intact airway not established | Limited |
| Anti-inflammatory activity (respiratory) | Animal/in vitro data; single group; specific targets not characterized independently | Limited |
| Human respiratory outcomes | No controlled trials identified; no RCT data | Not Established |
| Sequence-specific promoter binding (AEDL) | Computational modeling only; no independent structural validation | Limited |
| Human pharmacokinetics / safety | Not characterized in published studies | Not Established |
What We Still Don’t Know
- Whether bronchial epithelial gene expression effects are reproducible by independent investigators: All published observations of Bronchogen’s effects on bronchial epithelial gene expression originate from the Khavinson group. Independent replication using contemporary methods — including air-liquid interface culture, bronchial organoids, and transcriptomic profiling — is necessary to validate these findings.
- Whether in vitro observations translate to intact airway biology: Bronchial epithelial cells in standard monolayer culture differ substantially from the organized, pseudostratified epithelium in vivo, where cell-cell contacts, mucociliary architecture, submucosal signaling, and immune cell interactions all influence epithelial function. Effects observed in simplified culture models may not predict behavior in the intact airway.
- Whether animal model results translate to human respiratory disease: The animal models used in Khavinson bioregulator research typically involve young, otherwise healthy rodents. Human chronic airway disease involves decades of cumulative injury, remodeling, mucus hypersecretion, and immune dysregulation that is not well captured by acute animal models.
- The molecular basis for leucine-dependent bronchial tissue selectivity: The Khavinson hypothesis proposes that the C-terminal leucine in Bronchogen confers bronchial specificity relative to other AEDX bioregulators. The specific molecular mechanism — whether through receptor-mediated targeting, tissue-specific protease processing, or promoter complementarity — has not been established by independent experimental evidence.
- Pharmacokinetics following administration in humans: For a tetrapeptide of ~446 Da without protective modifications, proteolytic degradation in plasma is expected to be rapid. Whether sufficient intact AEDL peptide reaches bronchial epithelial cells in vivo following subcutaneous or other routes of administration has not been characterized in published pharmacokinetic studies.
6. Limitations of Current Research
References
- Khavinson VKh, Linkova NS, Kvetnoy IM, Mironova ES, Ilina AR. “Peptide regulation of gene expression and protein synthesis in bronchial epithelium.” Molecules. 2021;26(19):5957. doi:10.3390/molecules26195957
- Khavinson VKh, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Basel: Karger; 2005. Monograph covering the peptide bioregulator class including bronchial tissue bioregulator research.
- Anisimov VN, Khavinson VK. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Hiemstra PS, McCray PB Jr, Bals R. “The innate immune function of airway epithelial cells in inflammatory lung disease.” European Respiratory Journal. 2015;45(4):1150–1162. doi:10.1183/09031936.00141514 [Background reference on bronchial epithelial biology and its role in respiratory homeostasis.]
- Rock JR, Randell SH, Hogan BL. “Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling.” Disease Models & Mechanisms. 2010;3(9–10):545–556. doi:10.1242/dmm.006031 [Background reference on bronchial epithelial progenitor biology relevant to the renewal context discussed in this article.]